You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康臣藥業(01681.HK)2020年純利大增524.9%至4.99億元 末期息0.2港元
格隆匯 03-23 12:19

格隆匯3月23日丨康臣藥業(01681.HK)公佈,截至2020年12月31日止年度,公司實現收入17.53億元人民幣(單位下同),同比增長1.4%;公司權益股東應占溢利4.99億元,同比增長524.9%,倘扣除去年非現金項目的商譽及無形資產減值3.2億元影響,同比增長23.5%;每股基本盈利0.61元,宣派末期股息每股0.20港元。

按產品系列分類,腎科系列產品銷售較去年錄得增長約9.7%,其中尿毒清顆粒仍然是集團的皇牌產品,維持在腎病口服現代中成藥的領先地位;醫用成像對比劑銷售較去年減少約3.0%,仍穩佔國內磁共振成像對比劑市場的前列;骨傷系列產品銷售增長約19.5%;皮膚系列產品銷售減少約47.0%;肝膽系列產品銷售增長約13.2%;婦兒系列產品銷售增長約6.2%。整體銷售收入的增長主要是由於集團持續致力開拓產品市場以及發展全國各地的銷售網絡所致。

康臣業現在擁有“1+6”的產品格局,四條過億元產品線分別是腎科線(尿毒清顆粒、益腎化濕顆粒)、影像線(釓噴酸葡胺注射液、碘帕醇注射液)、骨傷科(正骨水、雲香祛風止痛酊)及婦兒線(右旋糖酐鐵口服溶液),預計消化線(緩痛止瀉軟膠囊等)1-2年內銷售額達到億元以上,各線均有主打的、重磅的產品。

2020年,公司利用自有資金不斷回購股票,全年共計回購了4590.7萬股股票,佔回購前總股本約5.30%,對自身股票的持續、大比例回購,既是對公司價值的認可和未來發展的堅定信心,也是對廣大投資者利益的保護,同時向資本市場傳遞積極正面的企業形象,是一項一舉多贏的戰略舉措。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account